ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 135 filers reported holding ROYALTY PHARMA PLC in Q3 2020. The put-call ratio across all filers is 1.34 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $114,264,692 | +1.9% | 4,210,195 | +15.4% | 0.02% | 0.0% |
Q2 2023 | $112,110,502 | +35.1% | 3,647,056 | +58.3% | 0.02% | +27.8% |
Q1 2023 | $82,989,520 | +71.9% | 2,303,345 | +88.6% | 0.02% | +63.6% |
Q4 2022 | $48,272,059 | -12.7% | 1,221,459 | -11.3% | 0.01% | -15.4% |
Q3 2022 | $55,316,000 | +33.4% | 1,376,705 | +39.6% | 0.01% | +44.4% |
Q2 2022 | $41,473,000 | -28.4% | 986,527 | -33.7% | 0.01% | -25.0% |
Q1 2022 | $57,958,000 | +11.4% | 1,487,630 | +13.9% | 0.01% | +20.0% |
Q4 2021 | $52,025,000 | +60.4% | 1,305,520 | +45.5% | 0.01% | +42.9% |
Q3 2021 | $32,432,000 | -23.3% | 897,403 | -13.1% | 0.01% | -30.0% |
Q2 2021 | $42,306,000 | +147.3% | 1,032,101 | +163.2% | 0.01% | +150.0% |
Q1 2021 | $17,107,000 | -35.2% | 392,170 | -25.7% | 0.00% | -42.9% |
Q4 2020 | $26,414,000 | +256.9% | 527,760 | +200.0% | 0.01% | +250.0% |
Q3 2020 | $7,400,000 | +401.4% | 175,903 | +478.6% | 0.00% | – |
Q2 2020 | $1,476,000 | – | 30,403 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
Brown University | 381,759 | $19,107,000 | 13.82% |
Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |